Compare Endeavour Silver Corp (EXK) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Cassava Sciences Inc — how do they compare? Endeavour Silver Corp trades at $7.46 (market cap $2.36B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Endeavour Silver Corp is far larger — about 44.4× Cassava Sciences Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EXK | FLNA | |
|---|---|---|
Market Cap | $2.36B | $53.14M |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $4.64 |
52-Week Low | $4.96 | $1.09 |
Enterprise Value | $2.36B | -$33.43M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $7.47, down 7.55% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 production of 3.4 million silver equivalent ounces and beat Q1 2026 earnings estimates with $0.21 EPS versus $0.10 expected. Despite negative net income margins and ROE, revenue growth is projected to improve from $468M in 2025 to $614M in 2026. Analyst sentiment remains positive with 78.57% buy ratings.
The outlook is mixed: operational momentum and silver price trends offer upside, but profitability challenges and high valuation ratios pose risks. Investors should weigh strong production growth against persistent negative earnings and cash flow concerns in a volatile commodity market.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
